Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice

Molecular Pharmaceutics

Volumn 9, Issue 9, 2012, Pages 2497-2504

  Iusuf, Dilek ^a   Sparidans, Rolf W ^b   Van Esch, Anita ^a   Hobbs, Mike ^c   Kenworthy, Kathryn E ^c   Van De Steeg, Evita ^a   Wagenaar, Els ^a   Beijnen, Jos H ^d   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

cholesterol lowering drugs; drug uptake transporters; liver exposure; myotoxicity; OATP1B1; plasma clearance

Indexed keywords

ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTING POLYPEPTIDES 1A; ORGANIC ANION TRANSPORTING POLYPEPTIDES 1B; PRAVASTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG UPTAKE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REGULATORY MECHANISM;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; INTESTINAL ABSORPTION; LIVER; MALE; MICE; MICE, KNOCKOUT; MICE, NUDE; ORGANIC ANION TRANSPORTERS; PRAVASTATIN;

EID: 84865979524     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300108c     Document Type: Article

References (35)

1. Hagenbuch, B.; Meier, P. J. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties Pflugers Arch. 2004, 447 (5) 653-665 (Pubitemid 38241451)
2. van de Steeg, E.; Stranecky, V.; Hartmannova, H.; Noskova, L.; Hrebicek, M.; Wagenaar, E.; van Esch, A.; de Waart, D. R.; Oude Elferink, R. P.; Kenworthy, K. E.; Sticova, E.; Al Edreesi, M.; Knisely, A. S.; Kmoch, S.; Jirsa, M.; Schinkel, A. H. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver J. Clin. Invest. 2012, 122 (2) 519-528
3. Kalliokoski, A.; Niemi, M. Impact of OATP transporters on pharmacokinetics Br. J. Pharmacol. 2009, 158 (3) 693-705
4. Kameyama, Y.; Yamashita, K.; Kobayashi, K.; Hosokawa, M.; Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B15, SLCO1B115 and SLCO1B115+C1007G, by using transient expression systems of HeLa and HEK293 cells Pharmacogenet. Genomics 2005, 15 (7) 513-522 (Pubitemid 41017600)
5. Nakai, D.; Nakagomi, R.; Furuta, Y.; Tokui, T.; Abe, T.; Ikeda, T.; Nishimura, K. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes J. Pharmacol. Exp. Ther. 2001, 297 (3) 861-867 (Pubitemid 32472480)
6. Chen, C.; Mireles, R. J.; Campbell, S. D.; Lin, J.; Mills, J. B.; Xu, J. J.; Smolarek, T. A. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1 Drug Metab. Dispos. 2005, 33 (4) 537-546 (Pubitemid 40393197)
7. Hirano, M.; Maeda, K.; Hayashi, H.; Kusuhara, H.; Sugiyama, Y. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin J. Pharmacol. Exp. Ther. 2005, 314 (2) 876-882 (Pubitemid 41043874)
8. Kivisto, K. T.; Grisk, O.; Hofmann, U.; Meissner, K.; Moritz, K. U.; Ritter, C.; Arnold, K. A.; Lutjoohann, D.; von Bergmann, K.; Kloting, I.; Eichelbaum, M.; Kroemer, H. K. Disposition of oral and intravenous pravastatin in MRP2-deficient TR-rats Drug Metab. Dispos. 2005, 33 (11) 1593-1596 (Pubitemid 41539954)
9. Singhvi, S. M.; Pan, H. Y.; Morrison, R. A.; Willard, D. A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects Br. J. Clin. Pharmacol. 1990, 29 (2) 239-243 (Pubitemid 20131424)
10. Kobayashi, D.; Nozawa, T.; Imai, K.; Nezu, J.; Tsuji, A.; Tamai, I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane J. Pharmacol. Exp. Ther. 2003, 306 (2) 703-708 (Pubitemid 36886171)
11. Niemi, M.; Pasanen, M. K.; Neuvonen, P. J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake Pharmacol. Rev. 2011, 63 (1) 157-181
12. Akao, H.; Polisecki, E.; Kajinami, K.; Trompet, S.; Robertson, M.; Ford, I.; Jukema, J. W.; de Craen, A. J.; Westendorp, R. G.; Shepherd, J.; Packard, C.; Buckley, B. M.; Schaefer, E. J. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly Atherosclerosis 2012, 220 (2) 413-417
13. Romaine, S. P.; Bailey, K. M.; Hall, A. S.; Balmforth, A. J. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy Pharmacogenomics J. 2010, 10 (1) 1-11
14. Zaher, H.; zu Schwabedissen, H. E.; Tirona, R. G.; Cox, M. L.; Obert, L. A.; Agrawal, N.; Palandra, J.; Stock, J. L.; Kim, R. B.; Ware, J. A. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin Mol. Pharmacol. 2008, 74 (2) 320-329
15. Chen, C.; Stock, J. L.; Liu, X.; Shi, J.; Van Deusen, J. W.; DiMattia, D. A.; Dullea, R. G.; de Morais, S. M. Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds Drug Metab. Dispos. 2008, 36 (9) 1840-1845
16. van de Steeg, E.; Wagenaar, E.; van der Kruijssen, C. M.; Burggraaff, J. E.; de Waart, D. R.; Elferink, R. P.; Kenworthy, K. E.; Schinkel, A. H. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs J. Clin. Invest. 2010, 120 (8) 2942-2952
17. van de Steeg, E.; van Esch, A.; Wagenaar, E.; van der Kruijssen, C. M.; van Tellingen, O.; Kenworthy, K. E.; Schinkel, A. H. High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel Clin. Cancer Res. 2011, 17, 294-301
18. Iusuf, D.; van de Steeg, E.; Schinkel, A. H. Functions of OATP1A and 1B transporters in vivo: insights from mouse models Trends Pharmacol. Sci. 2011, 33, 100-108
19. Sparidans, R. W.; Iusuf, D.; Schinkel, A. H.; Schellens, J. H.; Beijnen, J. H. Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates J. Chromatogr., B 2010, 879, 1851-1856
20. Van Zutphen, L. F. [Laboratory animals and animal experiments] Proefdieren en dierproeven 159 Tijdschr. Diergeneeskd. 1986, 111 (3) 121-131
21. Everett, D. W.; Chando, T. J.; Didonato, G. C.; Singhvi, S. M.; Pan, H. Y.; Weinstein, S. H. Biotransformation of pravastatin sodium in humans Drug Metab. Dispos. 1991, 19 (4) 740-748
22. Gridelli, B.; Scanlon, L.; Pellicci, R.; LaPointe, R.; DeWolf, A.; Seltman, H.; Diven, W.; Shaw, B.; Starzl, T.; Sanghvi, A. Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog 2 Transplantation 1986, 41 (3) 388-391 (Pubitemid 16117872)
23. Watanabe, T.; Kusuhara, H.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans J. Pharmacol. Exp. Ther. 2009, 328 (2) 652-662
24. Yamazaki, M.; Akiyama, S.; Nishigaki, R.; Sugiyama, Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats Pharm. Res. 1996, 13 (10) 1559-1564 (Pubitemid 26356962)
25. Glaeser, H.; Bailey, D. G.; Dresser, G. K.; Gregor, J. C.; Schwarz, U. I.; McGrath, J. S.; Jolicoeur, E.; Lee, W.; Leake, B. F.; Tirona, R. G.; Kim, R. B. Intestinal drug transporter expression and the impact of grapefruit juice in humans Clin. Pharmacol. Ther. 2007, 81 (3) 362-370 (Pubitemid 46364477)
26. Shirasaka, Y.; Suzuki, K.; Nakanishi, T.; Tamai, I. Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide Pharm. Res. 2010, 27 (10) 2141-2149
27. Shirasaka, Y.; Suzuki, K.; Nakanishi, T.; Tamai, I. Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein J. Pharm. Sci. 2011, 100, 3843-3853
28. Seithel, A.; Glaeser, H.; Fromm, M. F.; Konig, J. The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members Expert Opin. Drug Metab. Toxicol. 2008, 4 (1) 51-64 (Pubitemid 351234100)
29. Kyrklund, C.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance Clin. Pharmacol. Ther. 2003, 73 (6) 538-544 (Pubitemid 37249124)
30. Kyrklund, C.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects Br. J. Clin. Pharmacol. 2004, 57 (2) 181-187 (Pubitemid 38223530)
31. Regazzi, M. B.; Iacona, I.; Campana, C.; Raddato, V.; Lesi, C.; Perani, G.; Gavazzi, A.; Vigano, M. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients Transplant Proc. 1993, 25 (4) 2732-2734 (Pubitemid 23239614)
32. Igel, M.; Arnold, K. A.; Niemi, M.; Hofmann, U.; Schwab, M.; Lutjohann, D.; von Bergmann, K.; Eichelbaum, M.; Kivisto, K. T. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin Clin. Pharmacol. Ther. 2006, 79 (5) 419-426
33. Schindler, C.; Thorns, M.; Matschke, K.; Tugtekin, S. M.; Kirch, W. Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin Clin. Ther. 2007, 29 (1) 172-176 (Pubitemid 46414036)
34. Voora, D.; Shah, S. H.; Spasojevic, I.; Ali, S.; Reed, C. R.; Salisbury, B. A.; Ginsburg, G. S. The SLCO1B1*5 genetic variant is associated with statin-induced side effects J. Am. Coll. Cardiol. 2009, 54 (17) 1609-1616
35. Smith, P. F.; Eydelloth, R. S.; Grossman, S. J.; Stubbs, R. J.; Schwartz, M. S.; Germershausen, J. I.; Vyas, K. P.; Kari, P. H.; MacDonald, J. S. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies J. Pharmacol. Exp. Ther. 1991, 257 (3) 1225-1235